FunPep
Basic Information
- Stock Code
- 4881
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Tokyo
- Establishment Year
- October 2013
- Listing Year
- December 2020
- Official Website
- https://www.funpep.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- GNI Group, Heartseed, Nexel Pharma, DWTI, Medorex, Peptidream, SanBio, Helios, RenaScience, QualiPs, Takara Bio, Phoenix B, Japan Tissue Engineering
Overview
FunPep is a bio-pharmaceutical company based in Tokyo, established in 2013, focusing on drug development using its proprietary peptide technology.
Current Situation
FunPep maintains a sound financial foundation and focuses on research and development of pharmaceuticals using its proprietary peptide technology. In 2023, it discovered a candidate for a malaria treatment drug and aims to start clinical trials, expanding its advanced drug discovery pipeline. Its main business is bio-pharmaceutical development, where it possesses high technological capabilities amid competition with domestic and international bio-pharmaceutical companies, with growth expected. It is securing funds through stock acquisition rights issuance and third-party share allotments to prepare for future development investments. Headquartered in Tokyo, it leverages the benefits of the bio industry cluster to advance research collaborations. It also emphasizes sustainability, focusing on reducing environmental impact and conducting ethical research. In the future, it aims to expand its business scale through new pharmaceutical sales and partnership growth. In the volatile pharmaceutical development market, it focuses on achieving clinical success.
Trivia
Interesting Facts
- Acquired numerous patents within 10 years of establishment.
- Gaining attention for discovering a new malaria treatment drug candidate.
- Actively hiring young researchers to promote diversity.
- Belongs to Tokyo's bio cluster.
- Possesses unique peptide technology in drug discovery.
- Built a research organization geared toward clinical development.
- High funding efficiency, evaluated as a newcomer.
- Active in academic collaborations and technology transfers within the industry.
- Conducts multifaceted management including drug discovery support services.
- Established numerous joint ventures.
- Steadily building foundations for overseas expansion.
- Regular participant in life sciences trade shows.
- Aggressively partnering with mid-sized pharmaceutical companies.
- Early adopter of AI in technology development.
- Highly evaluated technology development in the researcher community
Hidden Connections
- Strong partnership hidden behind joint malaria drug research with Shionogi Pharmaceutical.
- Continuously receiving funding from Tokyo's drug discovery support fund.
- Partnered with overseas drug discovery ventures via licensing agreements.
- Known as a company applying University of Tokyo-originated bio technology.
- Technology development competition with Peptidream promotes innovation.
- Secured substantial investment from healthcare industry venture capital.
- Become a focus stock for institutional investors after TSE Mothers listing.
- Established collaborative relationships with domestic and international clinical development support organizations.
Future Outlook
Growth Drivers
- Global growth in peptide drug discovery
- Increasing demand for new therapeutic drug development
- Expansion of domestic and international pharmaceutical markets
- Drug discovery efficiency via AI technology utilization
- Strengthened collaborations with pharmaceutical companies
- High demand for infectious disease countermeasures products
- Government bio-medical support policies
- Expansion of licensing business
- Promotion of international joint research
- Recruitment and development of advanced technicians
- Application expansion to diverse disease areas
- Improved clinical trial success rates
Strategic Goals
- Initiate multiple clinical trials for new pharmaceutical candidates
- Start product sales and revenue generation domestically and internationally
- Diversify and expand technology pipeline
- Establish sustainable and ethical research and development framework
- Grow into a global leader in bio drug discovery
Business Segments
Drug Discovery Support Services
- Overview
- Drug discovery support and partnership provision using advanced peptide technology.
- Competitiveness
- Differentiation through advanced peptide synthesis and evaluation technologies
- Customers
-
- Domestic pharmaceutical companies
- Biotechnology companies
- University research institutions
- National research and development agencies
- Overseas bio companies
- Pharmaceutical development organizations
- License partners
- Products
-
- Peptide synthesis technology
- Drug discovery platform
- Efficacy evaluation services
- Molecular design support
- Clinical development support
- Patent technology licensing
- Safety evaluation
Pharmaceutical Development and Manufacturing Outsourcing
- Overview
- High-quality manufacturing outsourcing services supporting customers' pharmaceutical development.
- Competitiveness
- Possession of manufacturing technology for molecules challenging for conventional pharmaceuticals
- Customers
-
- Pharmaceutical companies
- Bio ventures
- Research institutions
- CRO companies
- Products
-
- Peptide pharmaceutical manufacturing outsourcing
- Quality management services
- Process development
- Formulation development
Technology Licensing and Joint Research
- Overview
- Supports provision of proprietary technology and joint advancement of research and development.
- Competitiveness
- Trusted relationships based on patented technologies and extensive research achievements
- Customers
-
- Overseas pharmaceutical companies
- Bio investors
- Academic institutions
- Contract research organizations
- Products
-
- Technology licensing agreements
- Joint research projects
- Intellectual property management
- Product commercialization support
Competitive Advantage
Strengths
- Proprietary peptide drug discovery platform
- Advanced molecular design and synthesis technology
- Solid funding base
- Candidate generation capability for clinical development
- Robust research and development organization
- Domestic and international joint research network
- Securing of specialized personnel
- Utilization of latest bio technologies
- Flexible funding activities
- Rapid decision-making processes
- High patent protection strength
- Response to pharmaceutical industry needs
- Strong commitment to clinical progress
- Convenience of Tokyo base
- High-transparency corporate governance
Competitive Advantages
- Possesses unique peptide sequence design technology not available elsewhere
- Accelerated research through collaborations with major pharmaceutical companies and research institutions
- Diverse generation of candidate molecules with clinical trials in mind
- Process optimization through high technological capabilities
- Flexible management via strong funding and stock acquisition rights issuance
- Rapid problem-solving by highly specialized technical team
- Technology deployment capability applicable to diverse disease areas
- Improved brand recognition in the bio drug discovery market
- Intellectual property strengthening based on patent strategy
- Strength in technology transfer and licensing partnerships
- Utilization of technologies for efficient pharmaceutical development processes
- Collaborative environment with research institutions near Tokyo
- Establishment of rigorous quality management systems
- Promotion of sustainable development goals
- Preparation for future multi-country expansion
Threats
- Intensifying competition in bio drug discovery
- Uncertainty and failure risks in clinical trials
- Risks of technology leakage or patent infringement
- Sudden changes in funding environment
- Development delays due to regulatory strengthening
- Technological innovations by new entrants
- Management changes in key partners
- Rising research and development costs
- Challenges in international market access
- Rapid changes in market needs
- Increasing compliance burden from external regulations
- Impact of global infectious disease outbreaks
Innovations
2023: Discovery of Malaria Treatment Drug Peptide Candidate
- Overview
- Developing a new malaria drug peptide jointly with Shionogi Pharmaceutical. Aiming to initiate clinical trials.
- Impact
- Successful entry into the infectious disease treatment field
2022: Introduction of New Peptide Synthesis Technology
- Overview
- Established efficient synthesis processes, achieving manufacturing cost reductions.
- Impact
- Shortened research and development periods and improved product price competitiveness
2024: Advanced Drug Discovery Platform
- Overview
- Introduced AI-based peptide design technology to improve generation efficiency.
- Impact
- Enhanced diversity and quality of candidate molecules
Sustainability
- Introduction of manufacturing processes to reduce environmental impact
- Promotion of animal testing alternative technologies
- Strengthening of research ethics and quality control
- Introduction of energy-saving equipment
- Enhanced collaboration activities with local communities